Known clinical prognostic factors were associated with all-cause mortality eg, higher risk of mortality with triple-negative breast cancer and advanced stage disease.2,19 It is worth noting that ERBB2-positive disease was associated with lack of receipt of GCC but may be influenced by the lack of coded data for receipt of ERBB2-targeted therapy in the NCDB. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.